In short. Approved biologicals, approved injectables, and the cell and exosome products that are sold entirely outside any approval.
Key points
- An approved material for a named use, a process that cannot be approved as a product, and a product that is generally not approved at all.
- A single sentence about regenerative treatments covers all three, and the sentence is true of none of them individually.
The regulatory position of this category is not one position. It is at least three, and each of the materials grouped under the word sits in one of them.
Approved for named uses
A small number of injectables and biologicals hold authorisations for defined indications, in defined populations, in defined markets. Those approvals are specific: they belong to a material and to a use, and their labelling states what the material is for and what its risks are. This is the only part of the category where a claim has been assessed against a standard, and the approvals are narrower than the way they are often described.
Prepared at the point of care
A preparation made in the room from the patient’s own blood is a process rather than a product. Product authorisation attaches to products, so there is no approved indication and no label, and the devices involved are regulated as laboratory equipment for what they do mechanically. Rules for blood-derived treatments differ between jurisdictions, so the position depends on where the treatment is given as well as on what is offered.
Three situations, routinely described as one
An approved material for a named use, a process that cannot be approved as a product, and a product that is generally not approved at all. A single sentence about regenerative treatments covers all three, and the sentence is true of none of them individually.
The third group, stated plainly
Cell and exosome products are generally not approved as cosmetic treatments, and regulators in several markets have issued warnings about advertising them as treatments for any condition. That is the clearest regulatory statement available in this subject and it is the one most often omitted from the marketing. Where such a product is offered, the questions are whether it is authorised at all, for what, in which market and by which authority. A description of what the product contains is not an answer to any of them.
Why the absence of approval is the relevant fact
An unapproved product has not been assessed for safety or for effect, has no defined composition that anybody is held to, and is not covered by the surveillance that would record harm if it occurred. For a product containing biological material, those gaps matter more than they would for a simple injectable, because sterility and long-term behaviour are the questions that most need answering and are least likely to be answered without an authorisation.
Three questions about a regulatory claim
- What is authorised here, for which indication, by which authority?
- If nothing is authorised, what is the basis on which it is being offered?
- Is the material tracked and reported on, or is an absence of reported harm simply an absence of reporting?
Approval is not the only question in this category and it is the one that decides most of the others, because it determines whether anybody has looked.
Frequently asked questions
Is anything approved as a regenerative treatment?
No. No authority approves a material as regenerative, because the word describes an intention rather than a composition or an indication. What exist are materials approved for named uses, and those approvals belong to those materials and those uses rather than to a class.
What is the status of cell and exosome products?
They are generally not approved as cosmetic treatments, and regulators in several markets have issued warnings about advertising them as treatments for any condition. Where one is offered, the relevant question is whether it is authorised at all, and the answer is usually that it is not.
Why does blood-derived treatment sit in a different position?
Because a preparation made at the point of care from the patient's own blood is a process rather than a product, so product authorisation does not attach to it. Rules for such treatments differ between jurisdictions, which means the position depends on where you are as well as on what is being offered.
Risks & Limitations
- The word regenerative describes a marketing position rather than an approved class, and no authority approves a material as regenerative.
- Cell and exosome products are generally not approved as cosmetic treatments, and warnings have been issued about advertising them as treatments.
- Most injected cells do not survive in useful numbers, which is the step that a claim of tissue rebuilding depends on.
- An absence of reported harm in an unapproved product is an absence of reporting rather than a finding of safety.
- A point-of-care preparation carries a risk of infection introduced during preparation, because blood handled outside a controlled laboratory is a medium in which bacteria grow.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after a procedure.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- Any new and persistent symptom after a procedure, or a change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — warnings and guidance on unapproved cell and exosome products
- European Medicines Agency (EMA) and national regulators — advanced therapy classification and guidance
- National Medical Products Administration (NMPA, China) — approved biological products and their indications
- World Health Organization (WHO) — guidance on cell and tissue-based therapies and their oversight
- Cochrane Library — systematic reviews of cell-based and platelet treatments for skin indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.